Fye Maintains Buy Rating on United Therapeutics with a Target Price of $464

Summary

Fye, a 5-star analyst, maintains a buy rating for United Therapeutics with a target price of $464, indicating a 17.59% upside from current levels. Oppenheimer also maintained a buy rating with a $575 target.Tip Ranks

Impact Analysis

So basically, Fye’s reaffirmation of a buy rating for United Therapeutics at a $464 target price is a vote of confidence amidst a backdrop of mixed analyst opinions and recent insider selling. The interesting part isn’t just the target price itself, but the timing—coming right after insider sales and a Q2 earnings miss, which might have otherwise spooked investors. This suggests that Fye sees underlying strengths or upcoming catalysts that could drive the stock higher, despite the recent hiccups. The market might be underestimating these potential positives, especially with Oppenheimer’s even higher target of $575 adding another layer of bullish sentiment. The risk here is whether these analysts’ expectations align with actual company performance, especially given the mixed ratings and varied price targets from other analysts. Watching how the stock reacts to these reaffirmations could reveal if the market is indeed asleep at the wheel or if skepticism is warranted.Tip Ranks+ 2